Atrial Fibrillation: Chronic Beta-blocker Use Versus As-needed Rate Control Guided by Implantable Cardiac Monitor
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The goal of this study is to test the feasibility of guiding as-needed pharmacological rate
control of atrial fibrillation (AF) by implantable cardiac monitors and to assess the impact
of continuous beta-blocker therapy versus as-needed rate control on the following outcomes:
(1) exercise capacity, (2) AF burden, (3) symptomatic heart failure, (4) biomarker assessment
of cardiac filling pressures and cardio-metabolic health, and (5) quality of life in patients
with atrial fibrillation and stage II or III heart failure with preserved ejection fraction.